Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Genfleet Therapeutics (Shanghai), Inc. Class H ( (HK:2595) ) has issued an update.
GenFleet Therapeutics has revised and adopted updated terms of reference for its board Audit Committee, effective 24 March 2026, to enhance governance and oversight. The committee, comprised mainly of independent non-executive directors with accounting or financial expertise, is mandated to supervise audits, internal controls and financial reporting, and to ensure the board can effectively monitor management.
The new terms clarify the committee’s authority over recommending the appointment, reappointment and removal of external auditors, setting their remuneration and managing non-audit services policies. They also formalize requirements on member independence, tenure and professional qualifications, while specifying that the Audit Committee will exercise supervisory functions and coordinate communication between management, internal departments and external auditors to improve transparency and regulatory compliance.
More about Genfleet Therapeutics (Shanghai), Inc. Class H
GenFleet Therapeutics (Shanghai) Inc. is a biopharmaceutical company based in the People’s Republic of China and listed in Hong Kong. The company operates under a board-led governance structure and is focused on strengthening oversight, audit quality and internal controls in line with the Hong Kong Listing Rules and Chinese corporate law.
Average Trading Volume: 1,619,374
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$10.31B
For an in-depth examination of 2595 stock, go to TipRanks’ Overview page.